Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A
Jayashree Motwani(Birmingham Children's Hospital), Gerald Spotts(Baxalta (United States)), Srilatha Tangada(Baxalta (United States)), Benoît Guillet(Inserm), Jan Blatný(University Hospital Brno), András Nagy(University of Szeged), Jennifer Doralt(Takeda (Austria)), Werner Engl(Takeda (Austria)), B. Wibaut(Institut Pasteur de Lille), Freimut H. Schilling(Luzerner Kantonsspital), Jimena Goldstine(Hollister (United States))
Cited by 0
Related Papers
A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms
|Cardiovascular Drugs and Therapy|2024|38
Selected Abstracts from the 12th Annual Meeting of the Clinical Immunology Society: 2021 Virtual Annual Meeting: Immune Deficiency and Dysregulation North American Conference
|Journal of Clinical Immunology|2021|28
Incidence of urinary tract infection following initiation of intermittent catheterization among patients with recent spinal cord injury in Germany and the Netherlands
|Journal of Spinal Cord Medicine|2020|18
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study
|Immunotherapy|2024|5
Vitamin D and breast cancer
|Orvosi Hetilap|2014|4